Coverage
— → Added to coverage
Investment conviction●●○○○2 of 5
Research target$85.00Stock price target
Investment thesis statusINTACTLast reviewed 7/16/26
Market cap$33.69BSnapshot value
Research history
See all GFS changes ↗What changed
GFS is a US-based specialty semiconductor foundry leveraged to the Physical AI buildout via three vectors: (1) silicon photonics/SCALE CPO platform for AI data center optical interconnects — addressing the copper bandwidth wall in GPU clusters; (2) automotive-grade MCUs and power management ICs for EV/ADAS/Physical AI systems (Renesas multi-billion partnership, top-3 auto MCU foundry); (3) CHIPS Act-funded $16B Western manufacturing expansion creating a geopolitical moat for defense/aerospace secure supply chains. Not a leading-edge node player — thesis rests on specialty processes where GF has qualification barriers and customer lock-in.
1) Q2 2026 earnings (Aug 2026): guidance $1.76B rev, Non-IFRS GM 28.5% — confirmation of margin recovery trajectory. 2) SCALE CPO design wins: industry-first OCI MSA-compliant co-packaged optics platform — hyperscaler adoption announcements would be a step-change catalyst. 3) Renesas multi-billion partnership ramp: expanding across FDX, BCD, CMOS for auto/data center power. 4) CHIPS Act funding milestones: $1.5B grant supporting $16B NY/VT fab expansion. 5) Investor Day 2029 target: $8.6B revenue implies ~6% CAGR from FY2025 $6.79B — photonics and auto mix shift drive margin expansion. 6) Quantum Technology Solutions division (May 2026): long-dated optionality, CHIPS R&D backed.
1) Silicon photonics/SCALE CPO fails to win hyperscaler adoption vs Broadcom/TSMC COUPE or pluggable optics — photonics stays a science project. 2) Revenue decline resumes: FY2025 $6.79B (down from FY2022 peak $8.1B) — if Q2-Q4 2026 show sequential deterioration, thesis is challenged. 3) Gross margins compress below 25% Non-IFRS — signals commodity foundry pricing, not specialty differentiation. 4) CHIPS Act funding clawed back or materially delayed under administration change. 5) Renesas partnership undershoots — design wins don't convert to wafer volume.
Bullish tilt — framed as 'overlooked AI infrastructure play' on X. Key narratives: silicon photonics/CPO as AI cluster bottleneck, CHIPS Act onshoring moat, Quantum division optionality. Analyst price targets $88–$125 (SA $88, Arete $95, Susquehanna $125). Caution on: margin trajectory, competitive pressure from TSMC/Broadcom in optics, wafer utilization rates. Sources: X search Jul 15 2026, @GlobalFoundries, @andiamonow, @SiversSemicond, @Remzztrades, @MelvinInvests.
Snapshot · 7/16/26🟡 Mixed · ins-$2.0M · 13F 22+/2-×0.0 · short↓0.11
Snapshot · 7/16/26